Article Information
History
- June 12, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.
Author Information
- Kshitij Srivastava1,
- Kamille A West1,
- Valeria De Giorgi1,
- Michael R Holbrook2,
- Nicolai V. Bovin3,4,
- Stephen M Henry4 and
- Willy A Flegel1,*
- 1Department of Transfusion Medicine, NIH Clinical Center, National Institutes of Health, Bethesda, MD, USA
- 2National Institute of Allergy and Infectious Diseases (NIAID) Integrated Research Facility, National Institutes of Health, Frederick, MD, USA
- 3Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow, Russia
- 4Centre for Kode Technology Innovation, School of Engineering, Computer and Mathematical Sciences, Faculty of Design and Creative Technologies, Auckland University of Technology, Auckland, New Zealand
- ↵*Address for correspondence: Willy Albert Flegel, MD, Laboratory Services Section, Department of Transfusion Medicine, NIH Clinical Center, National Institutes of Health; Bethesda MD 20892, USA, e-mail: waf{at}nih.gov, Phone: (301) 594-7401, FAX: (301) 496-9990
Authorship contribution: KS performed the SARS-CoV-2 kodecyte assay and wrote the manuscript; KAW provided the convalescent plasma samples and was in charge of the blood donors and collection; VDG provided the Ortho Total and IgG chemiluminescent assay results; MRH provided the virus neutralizing assay results; SMH and NVB designed the C19-kodecyte assay; WAF designed and coordinated the study and edited the manuscript. All authors discussed the study and reviewed the manuscript.
Posted June 12, 2021.
